Company: HCWB
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0000950170-25-046724
Chunk: 279

Company: HCW Biologics Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1B
Chunk 279
---
 2023; 250,000,000 shares    authorized and 44,541,295 shares issued at December 31, 2024

    3,603

    4,454

    Additional paid-in capital

    83,990,437

    93,781,511

    Accumulated deficit

    (70,532,323
    )

    (100,556,137
    )

    Total stockholders’ equity (deficit)

    13,461,717

    (6,770,172
    )

    Total liabilities and stockholders’ equity (deficit)
     
    $
    28,513,660

    $
    30,236,578

The accompanying notes are an integral part of these financial statements. 

99

HCW Biologics Inc. 

Statements of Operations 

    Years EndedDecember 31,

    2023

    2024

    Revenues:

    Revenues
     
    $
    2,841,794

    $
    2,566,792

    Cost of revenues

    (2,281,434
    )

    (1,607,389
    )

    Net revenues

    560,360

    959,403

    Operating expenses:

    Research and development

    7,676,316

    6,388,994

    General and administrative

    6,779,515

    6,839,596

    Legal expenses

    6,571,689

    15,910,480

    Reserve for credit losses and other expenses

    5,250,000

    1,300,000

    Total operating expenses

    26,277,520

    30,439,070

    Loss from operations

    (25,717,160
    )

    (29,479,667
    )

    Interest expense

    (283,042
    )

    (631,137
    )

    Other income, net

    1,005,925

    86,990

    Net loss
     
    $
    (24,994,277
    )
     
    $
    (30,023,814
    )

    Net loss per share, basic and diluted
     
    $
    (0.70
    )
     
    $
    (0.77